Search
Azacitidine
go.drugbank.com/drugs/DB00928ApprovedInvestigationalIt differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. … [A1415] The use of oral azacitidine for the treatment of AML in patients in complete remission was approved by the FDA in September 2020.[L35335]
Human cytomegalovirus immune globulin
go.drugbank.com/drugs/DB13886ApprovedInvestigationalThe seroprevalence of antibodies in adults ranges from 40-100 % with an inverse correlation to socioeconomic status. … Cytomegalovirus immunoglobulin is obtained from pooled adult human plasma selected for high titers of antibody for cytomegalovirus (CMV).
Ranibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigationalIn order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use. … [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO.
Lofexidine
go.drugbank.com/drugs/DB04948ApprovedInvestigational[A33084] It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. … [T209] Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018.[L2794]
Interferon alfa-2a
go.drugbank.com/drugs/DB00034ApprovedInvestigationalWithdrawnAn oral form is being developed by Amarillo Biosciences. … This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.
Serplulimab
go.drugbank.com/drugs/DB17451ApprovedInvestigationalSerplulimab is a humanized monoclonal IgG4 antibody that acts as an immune checkpoint inhibitor by targeting the programmed cell death-1 (PD-1) receptor.
Telotristat ethyl
go.drugbank.com/drugs/DB12095Approved[A252937, A252942] Currently, telotristat ethyl is used to treat carcinoid syndrome diarrhea from neuroendocrine tumors that are inadequately controlled by short-acting somatostatin analog (SSA) treatment … [A252937] The first line treatment of carcinoid syndrome diarrhea is SSA, but symptoms still reoccur over the course of the disease.[A252937]
Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[A189207,A189213] Previous agents within this class were efficacious but limited by liver toxicity - this led to the development of ubrogepant, which was designed to be a hepatoxicity-free alternative … [L10959] Several oral small molecule CGRP receptor antagonists, belonging to a class of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and [rimegepant]
Cefmetazole
go.drugbank.com/drugs/DB00274ApprovedIt has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.
Teduglutide
go.drugbank.com/drugs/DB08900ApprovedInvestigationalTeduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine). … The significance of this substitution is that teduglutide is longer acting than endogenous GLP-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. FDA approved on December 21, 2012.